Jasper Therapeutics, Inc., a biotechnology company that is revolutionizing the field of medicine with its novel antibody therapies, has announced the pricing of an underwritten public offering for the sale of 60,000,000 shares of its common stock. Each share will be sold at a public offering price of $1.50, for a total of $90 million in proceeds. These funds will be used to support general corporate purposes, such as capital expenditures, working capital, and general and administrative expenses. In addition, Jasper has granted the underwriters a 30-day option to purchase up to 9,000,000 additional shares. This offering is expected to close on or around January 27, 2023, pending the fulfillment of customary closing conditions.
Credit Suisse Securities (USA) LLC and William Blair & Company, L.L.C. are leading the charge as the active book-running managers for the proposed offering, while Oppenheimer & Co. Inc. is lending its support as the passive book-running manager. Together, they are committed to ensuring the success of this exciting offering.
Jasper is proud to offer securities through an effective “shelf” registration statement on Form S-3 (File No. 333-267777) that was filed with the Securities and Exchange Commission (SEC) on October 7, 2022 and declared effective by the SEC on October 18, 2022. To learn more about this offering, electronic copies of the preliminary prospectus supplement and the accompanying prospectus can be found on the SEC’s website or through Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C., or Syndicate Prospectus Department at 85 Broad Street, 26th Floor, New York. Don’t miss out on this exciting opportunity!
Jasper is a clinical-stage biotechnology company developing briquilimab, a powerful monoclonal antibody that targets c-Kit (CD117). This revolutionary therapy has the potential to treat chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS), as well as to be a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has been tested on over 130 dosed participants and healthy volunteers, demonstrating an impressive efficacy and safety profile, with exceptional clinical outcomes. Additionally, briquilimab is being further developed as a non-genotoxic conditioning agent for gene therapy, making it a true game-changer in the medical field.